Health and Fitness Health and Fitness
Tue, August 4, 2009
Mon, August 3, 2009
Sat, August 1, 2009
Fri, July 31, 2009

Genomic Health: Genomic Health Delivers Online Perspective


Published on 2009-07-31 12:10:39, Last Modified on 2009-07-31 12:10:49 - Market Wire
  Print publication without navigation


REDWOOD CITY, CA--(Marketwire - July 31, 2009) - As a leader in the field of personalized medicine, [ Genomic Health ] Inc. (NASDAQ: [ GHDX ]), is now lending its perspective on important industry issues, via an online Op-Ed column titled "Our Perspective." The current article, "Our Perspective, Three Essential Components of Healthcare Reform," articulates the company's belief that personalized medicine has the power to improve the quality of care, reduce costs, and ultimately provide relief for each facet of the American healthcare system -- from the payor to the [ patient ].

[ Genomic Health ] plans to use the column to weigh in on healthcare topics that are generating debate in Washington, on Wall Street and within the medical community. "We're looking forward to generating an Op-Ed type discussion," says [ Kim Popovits ], President and CEO of Genomic Health. "Whether it's related to diagnostics, cancer treatment issues or a breakthrough technology -- we think it's important for Genomic Health to have a voice in these online conversations and encourage readers to visit [ our website ] to learn more about the promise of [ personalized medicine." ]

About Genomic Health

[ Genomic Health ], Inc. (NASDAQ: [ GHDX ]) is a life science company focused on the development and commercialization of [ genomic-based ] clinical laboratory services for cancer that allow physicians and patients to make [ individualized treatment decisions ]. In 2004, Genomic Health launched the [ Oncotype DX ]® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its [ Oncotype DX colon cancer ] test in early 2010. The company was founded in [ 2000 ] and is located in Redwood City, California. For more information, please visit [ www.genomichealth.com ]

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

Links to third-party websites or pages are provided for convenience only. Each website is subject to its own terms of use, and we encourage you to consult these policy statements. Genomic Health has no control over third party sites and does not endorse or recommend these sites, and expressly disclaims any responsibility for the accuracy of content or opinions set forth in any third party website or your use of that information. In addition, Genomic Health disclaims all liability arising out of allegations that third party content infringes the intellectual property rights of any person. Information in this release should not be considered medical advice. Patients should consult their doctor to determine the appropriate treatment decision for their individual disease.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

Contributing Sources